Track bills, resolutions, and amendments moving through Congress
Measuring Illicit Fentanyl Trafficking Act
The bill strengthens DHS information sharing and accountability to improve detection and interdiction of illicit fentanyl, but raises privacy and civil‑liberties risks and adds administrative burdens with a risk of perverse incentives from metrics.
Stop Chinese Fentanyl Act of 2025
The bill strengthens U.S. tools, transparency, and targeted authorities to disrupt fentanyl supply chains while preserving ordinary goods trade, but it risks diplomatic escalation, new compliance and administrative costs, and constraints on some executive sanctions options.
HALT Fentanyl Act
The bill strengthens and speeds federal authority to target fentanyl-related substances—likely reducing availability and aiding enforcement—while imposing broader Schedule I coverage and accelerated rulemaking that may hinder legitimate research, raise compliance and enforcement costs, and increase risks of overbroad prosecutions.
HALT Fentanyl Act
The bill trades faster, broader legal tools and clearer definitions to deter and prosecute fentanyl-related substances and to allow some research continuity, against expanded criminal exposure, tighter research constraints and administrative/compliance burdens that may raise costs and limit access for researchers, providers, and some patients.
Expressing support for the designation of February 23, 2025, to March 1, 2025, as "National Fentanyl Awareness Week" and raising awareness of the negative impacts of fentanyl in the United States.
The resolution raises important awareness and data-driven responses to the deadly rise of fentanyl—likely improving prevention, naloxone access, and law-enforcement/public-health coordination—but risks steering policy and funding toward enforcement and alarm-driven, punitive responses instead of expanded treatment and harm-reduction.
Supporting the goals and ideals of Red Ribbon Week during the period of October 23 through October 31, 2025.
The resolution raises public awareness and promotes safe disposal and prevention messaging around fentanyl and other drugs, but its emphasis on symbolic actions and enforcement narratives risks diverting attention and resources from evidence‑based treatment and harm‑reduction, and may increase stigma for people who use drugs.
Designating August 21, 2025, as "Fentanyl Prevention and Awareness Day".
The resolution raises awareness and encourages education and coordination around illicit fentanyl, but as a symbolic, unfunded designation it may have limited practical impact and could unintentionally increase stigma or enforcement-driven harms without expanding treatment or harm-reduction services.
Commending Federal, State, and local law enforcement for their efforts in protecting Americans by combating drug trafficking and agroterrorism and for their recent actions in Kansas and across the country.
The resolution highlights and supports law-enforcement efforts that can reduce lethal drug supply and protect agriculture, but the trade-off is greater emphasis on enforcement—potentially higher taxpayer costs and risks to civil liberties and investments in treatment/prevention.
Supporting the mission and goals of National Fentanyl Awareness Day in 2025, including increasing individual and public awareness of the impact of fake or counterfeit fentanyl pills on families and young people.
The resolution raises awareness and supports documenting fentanyl threats to protect youth and guide agencies, but it risks creating alarm and encouraging punitive responses without committing funding or emphasizing treatment and harm reduction.
Joint Task Force to Counter Illicit Synthetic Narcotics Act of 2025
The bill centralizes and strengthens federal coordination, intelligence, and prosecutorial tools to disrupt synthetic‑opioid supply chains—potentially improving public safety and treatment deployment—while raising costs, civil‑liberty and privacy risks, oversight and federalism concerns, and diplomatic and local‑burden tradeoffs.
BUST FENTANYL Act
The bill strengthens U.S. tools and reporting to disrupt fentanyl and meth supply chains—especially those linked to the PRC—giving law enforcement faster sanctions and more focused intelligence at the cost of increased diplomatic tension, economic and compliance burdens for businesses, potential legal ambiguity, and higher administrative obligations.
HIDTA Enhancement Act
The bill channels sustained funding and DOJ support to strengthen law-enforcement responses to fentanyl trafficking and improve data-driven targeting, but it increases federal spending and carries risks of local resource diversion, prosecutorial disruption, and civil-liberties concerns if safeguards and offsets are not put in place.
Temporary Extension of Fentanyl-Related Substances Scheduling Act
Extending emergency scheduling keeps fentanyl analogues harder to obtain and preserves fast-acting enforcement tools, but it constrains research and imposes extra compliance and government costs.
Overdose RADAR Act
The bill strengthens overdose detection, coordination, and harm‑reduction/treatment capacity through federal grants and legal protections (faster, more targeted public‑health action) at the cost of increased ongoing local costs, administrative burdens, privacy risks, and potential shifts toward enforcement and regulatory uncertainty.
OPIOIDS Act
The bill aims to improve overdose detection, lab capacity, and interagency coordination—helping target public-health and enforcement responses—but increases privacy and civil‑liberty risks, may burden small labs or exclude under-resourced jurisdictions, and could shift spending toward enforcement rather than treatment.
Caribbean Border Counternarcotics Strategy Act
The bill centralizes and strengthens coordinated Caribbean counternarcotics efforts—potentially improving security and reducing violence in U.S. territories—while likely increasing federal costs and raising civil‑liberty and local‑policing trade-offs.
Combating Illicit Xylazine Act
The bill strengthens federal authority, reporting, and enforcement to curb xylazine misuse and improve data-driven public-health responses, but it risks criminalizing users, raising costs and compliance burdens for medical/veterinary suppliers, and creating short-term enforcement and resource strains without guaranteed concurrent expansion of treatment access.
Cannabis Administration and Opportunity Act
The bill ends federal criminal penalties for cannabis and creates a federal regulatory, research, and investment framework to expand market access and community reinvestment, but it does so at substantial taxpayer cost while imposing new regulatory compliance, administrative burdens, and lingering legal and privacy trade‑offs that may continue to complicate commerce and equity goals.
Duster Inhalation Prevention Act
The bill reduces inhalant-related harms—especially for youth—by banning certain high-risk propellants and empowering the CPSC to act quickly, at the cost of new compliance, reformulation, stockpile limits, and potential price/availability impacts for manufacturers, small businesses, consumers, and local governments.
Nitrous Oxide Inhalation Prevention Act
The bill prioritizes reducing youth nitrous‑oxide misuse and building prevention/oversight capacity, but does so at the cost of increased regulatory and compliance burdens for businesses and agencies, potential privacy impacts for purchasers, uncertain federal spending, and possible access impacts for legitimate medical and food‑service uses.
SAFE Banking Act of 2026
The bill substantially expands banking, payment, and mortgage access for state‑sanctioned cannabis and hemp markets and increases regulatory clarity, at the cost of higher compliance burdens, privacy/surveillance trade‑offs, persistent federal–state legal tensions, and some increased taxpayer or financial‑stability exposure.
Turn the Tide Act
The bill directs substantial new, multi‑year federal funding and several policy changes to expand opioid prevention, treatment, recovery housing, and workforce support—improving access for many in high‑burden areas—but does so at significant federal and state cost, with uneven geographic effects and added administrative and implementation complexity.
Fairness in Fentanyl Sentencing Act of 2025
The bill strengthens enforcement and interdiction of fentanyl-related substances (including faster sentencing guidance and funded mail screening) but risks broader criminalization, increased costs and operational strain for courts and postal services, reduced public input, and new privacy and patient-safety concerns.
Amend the Internal Revenue Code of 1986 to maintain the prohibition on allowing any deduction or credit associated with a trade or business involved in trafficking marijuana.
The bill clarifies and tightens federal tax rules to prevent taxpayers from subsidizing federally prohibited marijuana operations, but does so by imposing significantly higher tax burdens and regulatory friction on state-legal cannabis businesses, risking business closures, informal operations, and financial access problems.
PRESS Act
The bill aims to reduce illegally imported illicit drugs and strengthen prosecutorial tools by criminalizing pill‑making equipment tied to illicit importation, but does so in a way that risks criminalizing legitimate suppliers and increasing federal costs if enforcement expands.
Hemp Safety Enforcement Act
The bill increases State and Tribal control over hemp regulation and preserves interstate market access, at the cost of creating legal complexity, higher compliance burdens, and a likely patchwork of standards that could complicate supply chains and confuse consumers.
TIME for Overdose Justice Act
The bill removes the time limit on prosecuting drug-related deaths and serious injuries to expand accountability and potential deterrence, at the cost of greater risk to defendants' ability to mount fair defenses, increased prosecutorial leverage, and possible shifts in enforcement resources.
Protect Law Enforcement Task Forces Act
The bill centralizes and accelerates federal, prosecutor-led efforts against transnational organized crime—likely improving large-scale investigations and seizures—but does so at the risk of incentivizing asset-driven enforcement, stretching or redirecting resources, narrowing agency flexibility, and deprioritizing public-health alternatives to reduce demand.
Smarter Sentencing Act of 2026
The bill shifts federal drug sentencing and guideline processes toward shorter, more proportionate penalties and faster reform plus greater transparency, trading potential public‑safety and fiscal risks, administrative burdens, and possible diversion of savings away from rehabilitation programs for reduced incarceration and improved access to legal information.
No Fentanyl on Social Media Act
The bill requires a public, evidence-based report to inform parents, health officials, law enforcement, and lawmakers about how minors obtain fentanyl via social media—improving prevention and transparency but creating agency costs and risks to investigative secrecy, platform liability expectations, and potential burdens on smaller platforms.
